
Exclusive: UnitedHealth eyes $1 billion deal to exit Latin America as insurer refocuses on US, sources say
NEW YORK, June 9 (Reuters) - UnitedHealth Group (UNH.N), opens new tab is weighing multiple bids for its Latin American operations, according to two people with direct knowledge of the matter, as the insurer buckles down after a series of unprecedented missteps that include the ouster of its CEO and a reported criminal accounting probe.
The largest U.S. health insurer has been trying to exit Latin America since 2022, but the sale of Banmedica has taken on increasing urgency in recent months as the insurer took hits on multiple fronts, according to one of the people.
New CEO Steve Hemsley told shareholders last week that he was determined to earn back their trust after an earnings miss and a Wall Street Journal report that the company was under criminal investigation for alleged Medicare fraud. UnitedHealth has said it was not notified by the Department of Justice and that it stands by the integrity of its operations.
Hemsley replaced Andrew Witty as CEO, who had been in the post for only a matter of months following the murder of his predecessor, Brian Thompson, in New York in December while on his way to a meeting with investors.
The company has four non-binding bids for its Banmedica subsidiary, which operates in Colombia and Chile, for about $1 billion, according to both people, who asked not to be identified because the talks are private.
UnitedHealth's shares tumbled 25.5% in May alone and year-to-date are down 40%. UnitedHealth left Brazil in 2023 and Peru in March. It's aiming to get around $1 billion for Banmedica's operations in Colombia and Chile, the people said.
The two people said the company expects to set a deadline for binding proposals as soon as July.
UnitedHealth received bids from Washington, D.C.-based private equity firm Acon Investments; Sao Paulo-based private equity firm Patria Investments (PAX.O), opens new tab; Texas non-profit health firm Christus Health; and Lima-based healthcare and insurance provider Auna (GZ4.F), opens new tab, the people said. Auna is in talks with a financial partner, one of the sources added.
Banmedica's annual earnings before income taxes, depreciation and amortization, or EBITDA, is more than $200 million a year.
Patria and Christus Health declined to comment. UnitedHealth, Acon and Auna did not respond to requests for comment.
UnitedHealth bought Banmedica in 2018, opens new tab, with CEO David Scott saying he was "establishing a foundation for growth in South America for the next decades."
At the time, UnitedHealth paid around 12 times Banmedica's EBITDA, according to one of the people. Three years later, the insurer decided to leave Latin America as it grappled with losses in its largest operation in the region, Brazil's Amil, which had been acquired a decade earlier. It divested from its Brazilian operations in late 2023.
Banmedica is currently profitable, but is considered too small by UnitedHealth. It serves over 2.1 million consumers through its health insurance programs and has around 4 million patient visits annually across its network of 13 hospitals and 143 medical centers.
UnitedHealth booked an $8.3 billion loss last year related to the sale of its South American operations - $7.1 billion stemming from the Brazil exit and $1.2 billion from Banmedica.
"These losses relate to our strategic exit of South American markets and include significant losses related to foreign currency translation effects," the company said in a February filing.
Brazilian investment bank BTG Pactual (BPAC3.SA), opens new tab is advising UnitedHealth on the sale.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
32 minutes ago
- Reuters
Colombia to suspend fiscal rule as public finances worsen, source says
BOGOTA, June 10 (Reuters) - Colombia's government has authorized the use of an "escape clause" to temporarily suspend compliance with its fiscal rule, a government source told Reuters on Tuesday, amid deteriorating public finances. The fiscal rule, established in 2011 by Latin America's fourth-largest economy, imposes limits on government spending and debt to ensure the long-term sustainability of public finances and macroeconomic stability. The government's Higher Council for Fiscal Policy (CONFIS) met on Monday and authorized the suspension that will increase the South American nation's fiscal deficit from the government's 5.1% target. The finance ministry plans to hold a press conference on Friday to provide details about the decision and release its medium-term fiscal framework detailing new financing objectives. "It's possible that these include piecemeal austerity measures," wrote analysts at Capital Economics in a note. "But the government has a track record of missing its targets by a wide margin in recent years." The peso currency had weakened around 0.75% against the dollar in morning trading. "It doesn't look like the deterioration in the fiscal situation has been fully priced in (by the market) yet," the Capital Economics analysts said, adding that sovereign dollar bond spreads could widen a further 30 basis points. In 2024, Colombia logged a fiscal deficit of 6.8% of GDP, above the targeted 5.6%. While the government maintains that it adhered to the fiscal rule that year, analysts generally disagree. Last week, Finance Minister German Avila - a close ally of President Gustavo Petro - said that the government would roll out measures including increased borrowing and spending cuts, though he did not provide details. Colombia's autonomous committee on fiscal rule (CARF) previously estimated that the nation would need budget adjustments of between 40 trillion pesos ($9.74 billion) and 75 trillion pesos ($18.26 billion) to comply with the 5.1% deficit target. In mid-May, ratings agency Moody's said that Colombia's sovereign credit rating, currently at Baa2, was dependent on the "frank disclosure" of the country's fiscal figures in the forthcoming fiscal framework.


Reuters
2 hours ago
- Reuters
Colombian senator Uribe remains in critical condition after shooting
BOGOTA, June 10 (Reuters) - Colombian Senator Miguel Uribe, a potential presidential contender, remains in critical condition but is stable after being shot in Bogota on Saturday, the hospital treating him said on Tuesday. Uribe, 39, is a member of the opposition right-wing Democratic Center party and was shot in the head as he was addressing a campaign event in a public park in the capital. "We continue to take the necessary actions to mitigate the impact of the injuries," the Santa Fe Foundation hospital added in a statement, detailing that the senator remains in the ICU. The shooting, which was captured on video, has shaken Colombia, evoking the political violence of previous decades. Leftist President Gustavo Petro, who has vowed to bring peace to the country's conflict, said on Sunday he had ordered additional security for opposition leaders in response to more threats. He said that former president Alvaro Uribe, and right-wing politicians Maria Fernanda Cabal, Abelardo de la Espriella and Victoria Eugenia Davila will receive additional security immediately.


Reuters
7 hours ago
- Reuters
Sacyr sells Colombian assets for $1.6 billion
June 10 (Reuters) - Spanish engineering firm Sacyr ( opens new tab has agreed to sell its stake in three toll roads in different regions of Colombia for $1.6 billion, the company said on Tuesday, as it raises cash to expand in the United States. Infrastructure fund Actis will take over the assets in Colombia, Sacyr said in a filing to the stock market regulator. The transaction, which is expected to conclude in the second half of this year, will generate a cash inflow worth $318 million, it added. Sacyr, which focuses on motorway concessions, said earlier this year that it intended to sell assets in Colombia and Chile and was looking for partners to bid for larger and more lucrative highway projects in the U.S. where it competes with bigger construction firms.